FM4 656
CONTENTS
e u r o p e a n u r o l o g y , vo l . 7 2 , n o . 4 , Oc t o b e r 2 0 1 7
e83
The Platinum Hall of Fame http://dx.doi.org/10.1016/j.eururo.2017.07.046477
Immune Checkpoint Inhibition in Metastatic Urothelial CancerT. Powles, K. Smith, A. Stenzl, J. Bedke
Immune checkpoint inhibitors are a new treatment option in metastatic urothelial
cancer on the basis of available phase 2 and 3 trials. Predictive biomarkers are
needed. These should go beyond PD-L1 expression, which is showing inconsistent
results across trials.
482
If You Want to Make an Important Discovery, Listen to Your PatientsP.C. Walsh
No one knows more about certain aspects of a disease than the patient who has it.
So, listen to your patients and they may lead you in a direction in which no one else
is going.
483
Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the BladderT. Seisen, M. Sun, S.R. Lipsitz, F. Abdollah, J.J. Leow, M. Menon, M.A. Preston, L.C. Harshman,
A.S. Kibel, P.L. Nguyen, J. Bellmunt, T.K. Choueiri, Q.-D. Trinh
Trimodal therapy may be generally associated with adverse long-term overall
survival compared to radical cystectomy for muscle-invasive urothelial carcinoma of
the bladder. However, the survival benefit of radical cystectomy should be weighed
against the risks of surgery, especially in older patients.
488
Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details?G.S. Kulkarni, Z. Klaassen
489
Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? Eur Urol 2017;72:488–9 Using the National Cancer Data Base to Compare Treatment Modalities for Localized Muscle-invasive Bladder CancerT. Seisen, A.P. Cole, Q.-D. Trinh
492
Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk CategoriesL.H. Porter, M.G. Lawrence, D. Ilic, D. Clouston, D.M. Bolton, M. Frydenberg, D.G. Murphy,
C. Pezaro, G.P. Risbridger, R.A. Taylor
The prevalence of intraductal carcinoma of the prostate (IDC-P) is 2% in low-risk,
23% in moderate-risk, and 36% in high-risk cohorts, and is 56% in patients with
metastatic or recurrent disease. IDC-P warrants greater recognition and reporting,
particularly in high-risk prostate cancer.
496
Intraductal Carcinoma of the Prostate: Anonymous to OminousM.L.K. Chua, T.H. van der Kwast, R.G. Bristow
PlatinumOpinions
Platinum Priorities
Brief Correspondence,
Review Articles and
Original Articles together
with the Full Length Editorials
Brief Correspondence